newsfilter
← Latest News
PR Newswire·

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

ANIX
  • Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering Anixa Biosciences' ovarian cancer vaccine technology.
  • The patent includes methods for administering a nucleic acid encoding AMHR2 polypeptide to elicit an immune response for preventing or treating ovarian cancer.
  • The technology is exclusively licensed from Cleveland Clinic & developed in collaboration with the National Cancer Institute.
  • The vaccine targets high-risk populations, such as those with BRCA mutations or a family history of the disease.
  • This Canadian allowance expands Anixa's international intellectual property portfolio & complements existing U.S. patent protection issued in July 2025.
  • Anixa employs a "retired-protein" strategy to train the immune system to target ovarian cancer cells while avoiding harm to normal tissue.
  • Dr. Amit Kumar, Chairman & CEO, stated the allowance strengthens international protection & supports the company's broader cancer vaccine platform strategy.
  • Anixa's breast cancer vaccine recently completed a Phase 1 trial with all primary endpoints met & was funded by the U.S. Department of Defense.
  • The company continues to build an international intellectual property foundation to evaluate future clinical, regulatory, & strategic opportunities.
  • Anixa is also developing an ovarian cancer immunotherapy called lira-cel in collaboration with Moffitt Cancer Center.